Urticaria is a prevalent disease with substantial physical, psychological, and economic impacts. With the advent of understandings of the disease and the emerging evidence of treatments, the international guidelines for treating urticaria have been updated in recent years. In order to update the 2014 edition of the Taiwanese Dermatological Association (TDA) consensus of urticaria, a total of 17 dermatologists with extensive experience in urticaria management were invited to and attended the TDA consensus meetings. All the specific aspects of the content were approved by at least 75% of the experts in attendance. Comparing to the former edition, several substantial modifications were made. For diagnosis, D-dimer was added as the recommended routine test in patients with chronic spontaneous urticaria. For pharmacological management, treatment suggestions were simplified. The approved-dosed, the up-dosed second-generation antihistamines, omalizumab, and cyclosporine were listed as the first-line to the fourth-line treatment, respectively. In addition, the management for patients of special considerations, such as the elderly, children, and pregnant women, were all discussed and mentioned in the consensus. We hope the updated TDA consensus can serve as a reference for all physicians and can help the physicians providing up-to-dated managements for these patients.

荨麻疹是一种普遍的疾病，对身体、心理和经济有重大影响。随着对该病认识的出现和治疗的新证据，近年来国际上治疗荨麻疹的指南得到了更新。为更新2014版台湾皮肤病学会 (TDA) 荨麻疹共识，共邀请了17位具有丰富荨麻疹管理经验的皮肤科医生参加 TDA 共识会议。内容的所有具体方面都得到了至少75%的与会专家的批准。与前一版本相比，进行了几项实质性修改。诊断时，增加 D-二聚体作为慢性自发性荨麻疹患者推荐的常规检测。对于药物管理，简化了治疗建议。获批剂量、剂量增加的第二代抗组胺药奥马珠单抗和环孢素分别被列为四线治疗的一线药物。此外，共识中讨论并提及了特殊考虑患者的管理，如老年人、儿童和孕妇。我们希望更新的 TDA 共识可以作为所有医生的参考，并帮助医生为这些患者提供最新的管理。